Taiwan Biomaterial Co., Ltd. (TPEX:6649)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.80
-1.05 (-2.57%)
Mar 10, 2026, 12:18 PM CST
-7.44%
Market Cap 1.72B
Revenue (ttm) 203.27M
Net Income (ttm) 56.88M
Shares Out 42.00M
EPS (ttm) 1.35
PE Ratio 30.25
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,296
Average Volume 128,636
Open 40.85
Previous Close 40.85
Day's Range 39.80 - 40.85
52-Week Range 29.65 - 80.40
Beta 0.73
RSI 31.90
Earnings Date Mar 13, 2026

About Taiwan Biomaterial

Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It offers Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1921
Employees 35
Stock Exchange Taipei Exchange
Ticker Symbol 6649
Full Company Profile

Financial Performance

In 2024, Taiwan Biomaterial's revenue was 96.57 million, an increase of 32.59% compared to the previous year's 72.84 million. Losses were -1.73 million, -82.90% less than in 2023.

Financial Statements

News

There is no news available yet.